GT737 in Relapsing acute myeloid leukemia: NCT07676006 Clinical Landscape Report 2026
Explore the PatSnap Life Sciences MCP marketplace
This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.
Data snapshot: 16 September 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.
Early Phase 1
Clinical phase
Not yet recruiting
Recruitment status
36
Planned enrollment
2030-06-01
Primary-completion proxy
Executive view
NCT07676006 evaluates GT737 in Relapsing acute myeloid leukemia. The disclosed sponsor is Zhuhai Grit Biotechnology Co., Ltd., the design is Interventional, and the geographic footprint is China. The first listed primary endpoint is Proportion of participants experiencing dose limiting toxicity, assessed over 28 days.
The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.
PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.
How the MCP evidence stack was assembled
Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT07676006 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Relapsing acute myeloid leukemia landscape. Drug & Asset MCP drug_fetch was queried for GT737, while Company & Deal Intelligence MCP organization_fetch was queried for Zhuhai Grit Biotechnology Co., Ltd..
This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Readout proxy |
|---|---|---|---|---|---|---|
| NCT07676006 | GT737 | Early Phase 1 / Not yet recruiting | Zhuhai Grit Biotechnology Co., Ltd. | China | Proportion of participants experiencing dose limiting toxicity 28 days | 2030-06-01 |
| NCT07757672 | Cladribine | Phase 1/2 / Not yet recruiting | Sponsor not reported | Geography not reported | One year overall survival (OS) rate after treatment. One year | 2029-04-30 |
| NCT07758218 | AgenT-797 | Phase 1 / Not yet recruiting | University of Wisconsin-Madison | United States | Number Of Participants With Treatment-related Adverse Events Baseline through Day 29 post cell infusion | 2029-10-01 |
| NCT07754799 | Venetoclax | Phase 2 / Not yet recruiting | Hematology Hospital of Chinese Academy of Medical Sciences | Geography not reported | Event-free survival (EFS) up to 3 years | 2029-09-30 |
| NCT07755202 | Venetoclax | Phase 2 / Not yet recruiting | British Columbia Cancer Agency | Canada | Efficacy of triplet regimen on AML FLT3-wt participants From enrollment to the end of treatment at week 8 | 2029-10-01 |
The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.
Reproduce the trial-to-asset workflow with PatSnap MCP
Protocol design and endpoint interpretation
NCT07676006 is a Early Phase 1, not yet recruiting study with 36 planned participants. Allocation is N/A, masking is None (Open Label), and the intervention model is Single Group Assignment.
The primary endpoint is “Proportion of participants experiencing dose limiting toxicity” over “28 days.” The retrieved endpoint description is: The proportion of participants with dose-limiting toxicity (DLT) occurring within 28 days after infusion.
Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of 36 should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.
No named control drug was returned in the protocol field set. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.
Indexed readouts in the surrounding landscape
5 recent result records were selected as contextual evidence for Relapsing acute myeloid leukemia. These records do not establish direct evidence for NCT07676006 unless the registration number matches.
Vyxeos for Induction of Newly Diagnosed Low- or Intermediate-risk AML Patients, Age 18-70. A Pilot Study
Phase 2; n=20; Response Rate for Low/Intermediate Risk Acute Myeloid Leukemia (AML) After Induction With Vyxeos With or Without Mylotarg. = 6 Participants ; Response Rate for Low/Intermediate Risk Acute Myeloid Leukemia (AML) After Induction With Vyxeos With or Without Mylotarg. = 13 Participants Source: https://clinicaltrials.gov/ct2/show/results/NCT05599360
A Phase II Study of CPX-351 in Younger Patients < 60 Years Old With Secondary Acute Myeloid Leukemia
Phase 2; n=21; CR = 8 Participants Source: https://clinicaltrials.gov/ct2/show/results/NCT04269213
AAML1831: A Phase III Trial Comparing Standard Induction Therapy With CPX-351 in De Novo Pediatric AML: A Report From the Children's Oncology Group
Phase 3; n=721; EFS(2-year) = 62.2 % ; EFS(2-year) = 51.2 % Source: https://pubmed.ncbi.nlm.nih.gov/42497367/
Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.
Asset and sponsor context
GT737 is indexed as CAR-NKT with CD33 x CD70 biology and a global stage of Phase 1. The asset profile lists originator not reported as an originator or developer.
Zhuhai Grit Biotechnology Co., Ltd. is indexed in China with the website http://www.grit-bio.com. Develops tumor-infiltrating lymphocyte therapies The record lists 13 development-stage drug assets.
For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.
Development white space
- Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
- Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
- Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
- Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
- Sequencing white space. Clarify whether GT737 is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.
White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.
Strategic implications and next readouts
For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.
For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.
Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.
Source trail and bottom line
Anchor trial: NCT07676006
Protocol source: https://clinicaltrials.gov/study/NCT07676006
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 16 September 2026.
GT737 in Relapsing acute myeloid leukemia is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes Proportion of participants experiencing dose limiting toxicity and 2030-06-01 the leading decision points.
Build and refresh clinical landscape reports with PatSnap MCP
